Clinical Research Directory
Browse clinical research sites, groups, and studies.
SNV1521 in Participants with Advanced Solid Tumors
Sponsor: Synnovation Therapeutics, Inc.
Summary
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Official title: A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-02-23
Completion Date
2026-12
Last Updated
2025-03-13
Healthy Volunteers
No
Conditions
Interventions
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
Locations (9)
Yale University
New Haven, Connecticut, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
START Center for Cancer Care
West Valley City, Utah, United States
Scientia Clinical Research
Randwick, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Linear Clinical Research
Crawley, Western Australia, Australia